Top Markets
#1 Black Phoenix Black Phoenix +827.77%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +27.70%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.17%
#4 Bless Bless +22.57%
#5 pipedog pipedog +22.16%
#6 SAFEcoin SAFEcoin +20.09%
#7 Beam Beam +19.57%
#8 Magma Finance Magma Finance +19.26%
#9 PondCoin PondCoin +18.66%
#10 YFSX YFSX +15.99%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Zymeworks Inc. Zymeworks Inc.

Zymeworks Inc.

ZYME
Classement en actions #6243
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase,... Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Prix de l'action
$29.10
Capitalisation boursière
$2.14B
Changement (1 jour)
-0.71%
Changement (1 an)
94.89%
Pays
US
Échange Zymeworks Inc. (ZYME)

Catégorie

Healthcare
Revenus pour Zymeworks Inc. (ZYME)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Zymeworks Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Zymeworks Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH